Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN HYDROCHLORIDE.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs CLINDAMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Binds to the 50S ribosomal subunit, inhibiting peptide bond formation and bacterial protein synthesis.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
150-450 mg orally every 6 hours; maximum 1.8 g/day.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
The terminal elimination half-life of clindamycin is approximately 2-3 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life is prolonged to 8-12 hours. Renal impairment does not significantly alter half-life.
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Approximately 10-20% of clindamycin is excreted unchanged in urine; the remainder is hepatically metabolized and excreted in bile and feces as inactive metabolites. Fecal excretion accounts for about 4% of an administered dose as active drug and 60-70% as metabolites. Renal clearance is minor.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic